IRE-1α inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9867803
APP PUB NO 20170326104A1
SERIAL NO

15600473

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
FOSUN ORINOVE PHARMATECH INCUNIT 211 A4 218 XINGHU ST SUZHOU

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Patterson, John Bruce Ventura, US 12 37
Toro, Andras Oxnard, US 12 48
Wade, Warren Stanfield San Diego, US 7 15
Wu, Zhipeng Tianjin, CN 67 162
Yang, Yun Tianjin, CN 153 1335
Zeng, Qingping Thousand Oaks, US 37 239
Zubovics, Zoltan Budapest, HU 11 67

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 16, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 16, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00